EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Resistance of Gram-Negative Bacteria to Cefepime-Enmetazobactam: A Systematic Review

Matthew E Falagas, Laura T Romanos, Dimitrios S Kontogiannis, Katerina Tsiara, Stylianos A Kakoullis

Pathogens · 2025

DOI: 10.3390/pathogens14080777 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Pathogens, 2025. Verfasst von Matthew E Falagas und 4 weiteren Autor:innen. Beteiligte Einrichtung: Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, Marousi, 151 23 Athens, Greece. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Barbiturates, beta-Lactamase Inhibitors, Cefepime. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cefepime-enmetazobactam is a novel β-lactam/β-lactamase inhibitor combination showing good activity against multidrug-resistant (MDR) Gram-negative bacteria producing a variety of β-lactamases. In this systematic review, we aimed to evaluate the available data on resistance to this drug. We performed a thorough search of four databases (Embase, PubMed, Scopus, and Web of Science), as well as backward citation searching, to identify studies containing data on resistance to cefepime-enmetazobactam. The data were extracted and analyzed according to the breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Food and Drug Administration (FDA), or the specific breakpoints reported by the authors of the respective studies. Analysis based on the type of lactamases produced by the isolates was also performed. Ten studies reported in vitro susceptibility testing and mechanisms of antimicrobial resistance. The total number of isolates was 15,408. The activity of cefepime-enmetazobactam against β-lactamase-producing isolates was variable. The resistance of the studied extended-spectrum β-lactamase (ESBL)-producing and ampicillin C β-lactamase (AmpC)-producing isolates was low (0–2.8% and 0%, respectively). The resistance was higher among oxacillinase-48 β-lactamase (OXA-48)-producing and Klebsiella pneumoniae carbapenemase (KPC)-producing isolates (3.4–13.2% and 36.7–57.8%, respectively). High resistance was noted among metallo-β-lactamase (MBL)-producing isolates (reaching 87.5% in one study), especially those producing New Delhi metallo-β-lactamase (NDM) and Verona integron-encoded metallo-β-lactamase (VIM), which had the highest rates of resistance. The high activity of cefepime-enmetazobactam against Enterobacterales and selected lactose non-fermenting Gram-negative pathogens, including ESBL-producing and AmpC-producing isolates, makes it a potential carbapenem-sparing agent. The drug should be used after in vitro antimicrobial susceptibility testing in patients with infections caused by OXA-48, KPC, and MBL-producing isolates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsBarbituratesbeta-Lactamase InhibitorsCefepimeCephalosporinsDrug Resistance, BacterialDrug Resistance, Multiple, BacterialGram-Negative BacteriaHumansbeta-LactamasesGram-Negative Bacterial InfectionsMicrobial Sensitivity TestsTriazolesAzabicyclo Compounds

Stichwörter der Autor:innen

Acinerobacter baumanniiEnterobacteralesEscherichia coliKlebsiella pneumoniaePseudomonas aeruginosacefepimecefepime-enmetazobactamenmetazobactamlactose non-fermenting Gram-negativemetallo-β-lactamasesβ-lactamases

Substanzen

Anti-Bacterial AgentsBarbituratesbeta-Lactamase Inhibitorsbeta-LactamasesCefepimeCephalosporinsenmetazobactamTriazolesAzabicyclo Compounds

Autor:innen und Institutionen

  • Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, Marousi, 151 23 Athens, Greece.
  • School of Medicine, European University Cyprus, 6 Diogenous Str., 2404 Nicosia, Cyprus.
  • Department of Medicine, Tufts University School of Medicine, 145 Harrison Ave, Boston, MA 02111, USA.

Zitieren

APA

Falagas, M. E., Romanos, L. T., Kontogiannis, D. S., Tsiara, K., & Kakoullis, S. A. (2025). Resistance of Gram-Negative Bacteria to Cefepime-Enmetazobactam: A Systematic Review. Pathogens. https://doi.org/10.3390/pathogens14080777

Vancouver

Falagas ME, Romanos LT, Kontogiannis DS, Tsiara K, Kakoullis SA. Resistance of Gram-Negative Bacteria to Cefepime-Enmetazobactam: A Systematic Review. Pathogens. 2025. doi:10.3390/pathogens14080777

BibTeX
@article{Falagas2025,
  author = {Falagas, Matthew E and Romanos, Laura T and Kontogiannis, Dimitrios S and Tsiara, Katerina and Kakoullis, Stylianos A},
  title = {Resistance of Gram-Negative Bacteria to Cefepime-Enmetazobactam: A Systematic Review},
  journal = {Pathogens},
  year = {2025},
  doi = {10.3390/pathogens14080777}
}
Kostenlos starten →